117 related articles for article (PubMed ID: 35282741)
1. Olfactory threshold predicts treatment response in relapsing multiple sclerosis.
Bsteh G; Hegen H; Berek K; Altmann P; Auer M; Di Pauli F; Haider L; Leutmezer F; Rommer P; Walchhofer LM; Wurth S; Zinganell A; Deisenhammer F; Berger T
Mult Scler; 2022 Sep; 28(10):1541-1552. PubMed ID: 35282741
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
[TBL] [Abstract][Full Text] [Related]
3. Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis.
Bsteh G; Hegen H; Altmann P; Auer M; Berek K; Di Pauli F; Leutmezer F; Rommer P; Wurth S; Zinganell A; Zrzavy T; Deisenhammer F; Berger T
Eur J Neurol; 2021 Jun; 28(6):2037-2045. PubMed ID: 33735479
[TBL] [Abstract][Full Text] [Related]
4. Transient impairment of olfactory threshold in acute multiple sclerosis relapse.
Bsteh G; Hegen H; Ladstätter F; Berek K; Amprosi M; Wurth S; Auer M; Di Pauli F; Deisenhammer F; Lutterotti A; Berger T
Mult Scler Relat Disord; 2018 Jul; 23():74-77. PubMed ID: 29783156
[TBL] [Abstract][Full Text] [Related]
5. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
Portaccio E; Bellinvia A; Fonderico M; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Confalonieri P; Protti A; Sola P; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Filippi M; Trojano M; Amato MP
Brain; 2022 Aug; 145(8):2796-2805. PubMed ID: 35325059
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.
Vermersch P; Oreja-Guevara C; Siva A; Van Wijmeersch B; Wiendl H; Wuerfel J; Buffels R; Kadner K; Kuenzel T; Comi G;
Eur J Neurol; 2022 Mar; 29(3):790-801. PubMed ID: 34748672
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
8. Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies.
Wnuk M; Drabik L; Marona M; Szaleniec J; Bryll A; Karcz P; Kolasinska J; Kolasinska M; Ziekiewicz M; Skladzien J; Popiela T; Slowik A
Ear Nose Throat J; 2022 Dec; 101(10):640-644. PubMed ID: 33236917
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
Bsteh G; Feige J; Ehling R; Auer M; Hegen H; Di Pauli F; Deisenhammer F; Reindl M; Berger T
Mult Scler; 2017 Aug; 23(9):1241-1248. PubMed ID: 27765877
[TBL] [Abstract][Full Text] [Related]
10. Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate.
Jožef M; Locatelli I; Brecl Jakob G; Rot U; Kos M
Mult Scler Relat Disord; 2023 Apr; 72():104615. PubMed ID: 36933300
[TBL] [Abstract][Full Text] [Related]
11. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C
JAMA Neurol; 2022 Jul; 79(7):682-692. PubMed ID: 35575778
[TBL] [Abstract][Full Text] [Related]
12. Odour discrimination and identification as a biomarker of long-term disability worsening in multiple sclerosis.
Berek K; Hegen H; Auer M; Barket R; Di Pauli F; Hocher J; Krajnc N; Zinganell A; Deisenhammer F; Berger T; Bsteh G
Mult Scler; 2024 Jan; 30(1):55-62. PubMed ID: 37850472
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
[TBL] [Abstract][Full Text] [Related]
14. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
[TBL] [Abstract][Full Text] [Related]
15. Change of olfactory function as a marker of inflammatory activity and disability progression in MS.
Bsteh G; Hegen H; Ladstätter F; Berek K; Amprosi M; Wurth S; Auer M; Di Pauli F; Deisenhammer F; Reindl M; Berger T; Lutterotti A
Mult Scler; 2019 Feb; 25(2):267-274. PubMed ID: 29185867
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
[TBL] [Abstract][Full Text] [Related]
17. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
Boffa G; Lapucci C; Sbragia E; Varaldo R; Raiola AM; Currò D; Roccatagliata L; Capello E; Laroni A; Mikulska M; Gualandi F; Uccelli A; Angelucci E; Mancardi GL; Inglese M
Eur J Neurol; 2020 Oct; 27(10):2047-2055. PubMed ID: 32418281
[TBL] [Abstract][Full Text] [Related]
18. Retinal layer thickness predicts disability accumulation in early relapsing multiple sclerosis.
Bsteh G; Hegen H; Altmann P; Auer M; Berek K; Di Pauli F; Haider L; Kornek B; Krajnc N; Leutmezer F; Macher S; Rommer P; Walchhofer LM; Zebenholzer K; Zulehner G; Deisenhammer F; Pemp B; Berger T
Eur J Neurol; 2023 Apr; 30(4):1025-1034. PubMed ID: 36719184
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
